🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Head and Neck Squamous Cell Carcinoma

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma NCT06753747Phase 1, Phase 21 site📍 Chengdu West China Hospital · Tests: Palbociclib, Afatinib(30mg), Afatinib(40mg), Afatinib(RP2D) EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC NCT07617805Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma NCT07217028Phase 11 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET) AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy NCT06494995Phase 21 site📍 Shanghai Fudan University · Tests: Cadonilimab, Low-dose radiotherapy, SBRT, Capecitabine Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma NCT07337161NA1 site📍 London David Palma · Tests: SBRT, Standard Radiation A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site📍 Taipei AP Biosciences Inc. · Tests: AP203, AP203 Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) NCT07485296Phase 21 site📍 Rozzano Gruppo Oncologico del Nord-Ovest · Tests: Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., place… Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT NCT07448727n/a1 site📍 Rome University of Rome Tor Vergata Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT07744126Phase 24 sites📍 Duarte📍 Newnan📍 Taichung AbbVie · Tests: Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. NCT07791745Phase 2, Phase 31 site📍 Shanghai Taizhou Mabtech Pharmaceutical Co.,Ltd · Tests: Enlituo® + Anyouping® + PBC, Placebo-Enlituo + Anyouping® + PBC TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread NCT07726199NA1 site📍 Kolhāpur Kolhapur Cancer Centre - Cancer Centers of America · Tests: Selective Neck Dissection (Levels I-IV), Intervention : Selective Neck Dissection (Levels I-III) A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 A Study of IDP-001 in Advanced or Metastatic Solid Tumors NCT07602842Phase 1, Phase 26 sites📍 Los Angeles📍 Sarasota📍 Indianapolis InduPro, Inc. · Tests: IDP-001 Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma NCT07768189Phase 3111 sites📍 Huntsville📍 Tucson📍 Duarte Corbus Pharmaceuticals Inc. · Tests: CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962EARLY Phase 15 sites📍 Kingswood📍 Wollongong📍 Southport Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD204 Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China NCT04857164Phase 21 site📍 Beijing Yuankai Shi · Tests: Pembrolizumab combined with Chemotherapy Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC NCT07088211Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: Sacituzumab Tirumotecan and Toripalimab Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer NCT06138028Phase 2, Phase 32 sites📍 Qingdao📍 Qingdao Qingdao Central Hospital · Tests: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab） Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN NCT07264075Phase 31 site📍 Le Havre Groupe Oncologie Radiotherapie Tete et Cou · Tests: Ivonescimab 10 mg/kg, Ligufalimab, Pembrolizumab (KEYTRUDA ®) Effects of Infusion Timing on Treatment Response in Solid Tumors NCT07630168Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-… A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863Phase 121 sites📍 Scottsdale📍 Tucson📍 Los Angeles Clasp Therapeutics, Inc. · Tests: CLSP-1025 A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants NCT07668154Phase 22 sites📍 Chengdu📍 Shanghai Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB571, Pembrolizumab, carboplatin, Cisplatin Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants NCT00898638n/a4 sites📍 Nashville📍 Nashville📍 Nashville Vanderbilt University Medical Center · Tests: biologic sample preservation procedure, medical chart review A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) NCT07408063Phase 21 site📍 Toronto University Health Network, Toronto · Tests: GSK5764227, Dostarlimab A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN NCT05751512Phase 31 site📍 Shanghai Lepu Biopharma Co., Ltd. · Tests: MRG003, Cetuximab injection, Methotrexate Injection
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy